Ajanta Pharma Limited
NSE: AJANTPHARMMarket Closed • NSE
Day range
52 week range
Ajanta Pharma Limited closed at INR3329.00 (-0.9%) on volume 0.38x its 20-day average, trading 12.3% below its 52-week high.
2026-Q2
Q2 FY2026 Financial Results
PAT moved +25.1% QoQ
2026-08-05
DIVIDEND Announced
Interim Dividend - Rs 32 Per Share
2025-11-10
DIVIDEND Announced
Interim Dividend - Rs 28 Per Share
Revenue and PAT bars use independent scales to make their year-on-year direction readable.
Complete reported financial history · Values use the company's reporting currency
Hover over the chart for exact reported values. Percentage lines use the right-hand axis.
A 0–100 quantitative summary of reported fundamentals. Use the underlying financials and risks for context; the score is not a buy or sell recommendation.
Strengths
Strong Capital Efficiency: ROCE stands at 34.5%
Low Debt Profile: Debt-to-Equity is comfortable at 0.06x
Risks
Subject to cyclical raw material and macro industry pressures
Bull case
Market Leadership: Established operational scale in Drug Manufacturers - Specialty & Generic.
Bear case
Macro Headwinds: Fluctuations in interest rates and sector-specific policy shifts could compress multiples.
Flip condition
Sustained quarterly EBITDA margin expansion above 20% would trigger an upgrade.
Ownership distribution
Category trends
Hover over a period for exact holdings
Complete dividend, bonus, split, rights and other action history
| Record date | Corporate action | Information | Announcement date | Ex-date |
|---|---|---|---|---|
| 05 Aug 2026 | Dividend | ₹32.00 / share | — | 05 Aug 2026 |
| 10 Nov 2025 | Dividend | ₹28.00 / share | — | 10 Nov 2025 |
| 06 Nov 2024 | Dividend | ₹28.00 / share | — | 06 Nov 2024 |
| 30 May 2024 | Buy Back | Buy Back | — | 30 May 2024 |
| 08 Feb 2024 | Dividend | ₹26.00 / share | — | 08 Feb 2024 |
| 04 Aug 2023 | Dividend | ₹10.00 / share | — | 04 Aug 2023 |
| 24 Mar 2023 | Buy Back | Buy Back | — | 24 Mar 2023 |
| 14 Nov 2022 | Dividend | ₹7.00 / share | — | 11 Nov 2022 |
| 23 Jun 2022 | Bonus issue | 1:2 bonus ratio | — | 22 Jun 2022 |
| 14 Jan 2022 | Buyback | Buyback | — | 13 Jan 2022 |
| 10 Nov 2021 | Dividend | ₹9.50 / share | — | 09 Nov 2021 |
| 13 Nov 2020 | Buyback | Buyback | — | 12 Nov 2020 |
| 13 Nov 2020 | Dividend | ₹9.50 / share | — | 12 Nov 2020 |
| — | Annual General Meeting | Annual General Meeting | — | 21 Jul 2020 |
| 18 Nov 2019 | Dividend | ₹13.00 / share | — | 15 Nov 2019 |
| — | Annual General Meeting | Annual General Meeting | — | 09 Jul 2019 |
| 12 Feb 2019 | Buy Back | Buy Back | — | 11 Feb 2019 |
| 12 Nov 2018 | Dividend | ₹9.00 / share | — | 09 Nov 2018 |
| — | Annual General Meeting | Annual General Meeting | — | 26 Jun 2018 |
| — | Annual General Meeting | Annual General Meeting | — | 23 Jun 2017 |
| 25 Mar 2017 | Dividend | ₹7.00 / share | — | 23 Mar 2017 |
| 08 Nov 2016 | Dividend | ₹6.00 / share | — | 07 Nov 2016 |
| — | Annual General Meeting | Annual General Meeting | — | 24 Jun 2016 |
| 19 Mar 2016 | Dividend | ₹8.00 / share | — | 17 Mar 2016 |
| — | Dividend | ₹6.00 / share | — | 25 Jun 2015 |
Traded volume and delivery percentage across the latest 20 sessions
Compare valuation, latest quarterly performance and year-on-year growth
| Company name | Market cap ₹ Cr | P/E ratio | Dividend yield % | Quarterly sales ₹ Cr | Profit after tax ₹ Cr | Sales growth % | Profit growth % |
|---|---|---|---|---|---|---|---|
 Sun Pharmaceutical Industries LimitedSUNPHARMA Open analysis | ₹4.22L | 34.90 | 0.91% | ₹15,300.00 | ₹2,901.00 | +10.46% | +26.52% |
 Divi's Laboratories LimitedDIVISLAB Open analysis | ₹2.43L | 82.97 | 0.33% | ₹3,080.00 | ₹902.00 | +27.80% | +65.50% |
 Torrent Pharmaceuticals LimitedTORNTPHARM Open analysis | ₹1.73L | 72.83 | 0.83% | ₹4,128.00 | ₹389.00 | +41.90% | -21.89% |
 Apollo Hospitals Enterprise LimitedAPOLLOHOSP Open analysis | ₹1.13L | 54.32 | 0.25% | ₹7,044.00 | ₹610.00 | +20.58% | +38.32% |
 Zydus Lifesciences LimitedZYDUSLIFE Open analysis | ₹1.12L | 25.03 | 0.09% | ₹8,017.00 | ₹990.00 | +21.95% | -34.91% |
 LENSKART SOLUTIONS LTDLENSKART Open analysis | ₹1.12L | 174.73 | 0.00% | ₹2,714.00 | ₹228.00 | +43.29% | +273.77% |
 Laurus Labs LimitedLAURUSLABS Open analysis | ₹1.11L | 101.83 | 0.12% | ₹2,026.31 | ₹367.60 | +29.10% | +125.49% |
 Cipla LimitedCIPLA Open analysis | ₹1.07L | 31.78 | 0.98% | ₹7,119.00 | ₹786.00 | +2.33% | -39.16% |
Ajanta Pharma is primarily engaged in development, manufacturing and marketing of speciality pharmaceutical quality finished dosages.(Source : 202003-01 Annual Report Page No:70).
IndiaHealthcare
Is Ajanta Pharma Limited Shariah compliant?
Ajanta Pharma Limited is currently screened as Shariah Compliant under AAOIFI Shariah Standard No. 21. Business activities align with Shariah permissible sectors. Debt to Market Cap (0.63%) complies with AAOIFI threshold (≤ 33%).
What is Ajanta Pharma Limited's current valuation relative to peers?
Ajanta Pharma Limited trades at a P/E of 36.7x compared to the sector median of 37x, and a Price-to-Book of 9.2x.
Is the company financially healthy?
The company has a Debt-to-Equity ratio of 0.06x. Interest coverage is 82.3x.
What are the historical revenue and profit growth rates?
Over the past 5 years, revenue compounded at -0.2% while net profit growth averaged 0%.
Market data is informational and may be delayed. Shariah screening follows the displayed methodology. This is not investment advice.
Market data may be delayed. Quote date: 2026-10-16. Financial figures relate to their stated reporting periods. This information is for research and is not a recommendation to buy or sell.